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Thoracic Oncology Clinic
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Barbara Cashavelly, MSN, RN, AOCN,* and Thomas J. Lynch, MD*
Introduction: Fatigue is one of the most common symptoms in
patients with advanced cancers. Despite its high prevalence, it is
often unrecognized and undetected. This study assessed the feasi-
bility and validity of a one-item fatigue scale (OIFS) in an outpatient
oncology clinic.
Methods: Over a 3-month trial period, all patients in a thoracic
oncology clinic were screened for fatigue with a one-item, 0 to 10
scale. Over a second trial period, an additional sample of 100 clinic
patients completed validated measures of fatigue, including the
Functional Assessment of Chronic Illness Therapy-Fatigue Scale
(FACIT-F) and Fatigue Symptom Inventory (FSI), in addition to the
OIFS.
Results: During the initial trial period, more than 95% of patients
(574 of 600) had a documented OIFS score on their first clinic visit.
Data from the second cohort of patients revealed that the OIFS had
good test-retest reliability (r  0.88) and was highly correlated with
the FSI severity scale (0.87) and the FACIT-F (0.75). Receiver
operating characteristic analysis showed the OIFS had good discrim-
ination compared with the FACIT-F (area under the curve  0.87).
Sensitivity and specificity of several OIFS cutoff scores were com-
pared, and scores between 3 and 5 were found to be optimal.
Conclusions: The use of a one-item scale to screen for fatigue is
feasible in an ambulatory clinic setting. This scale had convergent
validity with other measures of fatigue and was able to identify cases
of fatigue that met criteria on the FACIT-F. These data support the
recommendations in the National Comprehensive Cancer Network
guidelines for cancer-related fatigue screening.
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Fatigue is one of the most prevalent and distressing symp-toms among patients with cancer. Cancer-related fatigue
(CRF) differs from the fatigue experienced by healthy people
because it is unrelieved by rest or sleep.1 The National
Comprehensive Cancer Network (NCCN) defines CRF as “a
persistent, subjective sense of tiredness related to cancer or
cancer treatment that interferes with usual functioning.”2
Estimates of the prevalence of CRF range from 60% to
90%.3–5 Fatigue is the most common side effect in patients
undergoing chemotherapy or radiation.6 Although fatigue is a
common symptom at the time of cancer diagnosis, it in-
creases in prevalence and intensity with therapy and cancer
progression.7 A study of more than 3000 cancer patients
demonstrated that nearly twice as many patients reported
fatigue as pain.8 Studies show the prevalence of fatigue in
ambulatory patients with advanced-stage lung cancer is as
high 81.5%.9
CRF is very distressing to patients as it interferes with
their ability to remain functionally independent and active.10
Multiple studies have shown that fatigue negatively affects
enjoyment and quality of life (QOL). The studies performed
by the Fatigue Coalition illustrate the impact of fatigue on
QOL.3,11 More than 75% of the cancer survivors in this study
experienced fatigue at least a few days of the month while
receiving chemotherapy. Of these patients, 91% reported that
fatigue prevented them from experiencing a normal life, and
88% responded that it caused them to alter their daily rou-
tine.11 A similar study found that most patients ranked fatigue
as the side effect that most affected them during therapy,
significantly more than nausea, hair loss, or pain.12
Despite its prevalence and impact, cancer-related fa-
tigue is often overlooked in clinical practice because oncol-
ogy clinicians tend to focus their limited time discussing
anti-cancer therapy with their patients. There are many pa-
tient and clinician barriers to effective communication about
fatigue.13 One of the most widely recognized obstacles is that
cancer patients often fail to communicate the symptom to
their clinicians.3,12,14 A study of 200 ambulatory cancer pa-
tients receiving chemotherapy revealed that 66% did not
discuss fatigue with their physician.15 Many of the patients
reported that they did not communicate their fatigue because
of a lack of awareness of possible treatments. These findings
suggest that clinicians are not educating patients about the
prevalence and potential therapies for CRF.
The first step toward improving the management of
CRF is for clinicians to recognize it in their patients. The
NCCN guidelines recommend screening every patient at
regular intervals for fatigue as part of the vital signs.2 They
recommend screening with the question, “Since your last
visit, how would you rate your worst fatigue on a scale of 0
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to 10?” Scores on this scale are given corresponding categor-
ical descriptions: no fatigue (0), mild fatigue (1–3), moderate
fatigue (4–6), and severe fatigue (7–10). Although the
NCCN recommends this screening tool at each initial visit
and at regular intervals, few data exist on the feasibility or
validity of this screening.
Any screening tool for CRF must be easy to administer
in an ambulatory practice and be clinically meaningful. A
one-item scale for fatigue could easily be incorporated in any
clinical setting. Support for the use of a 0- to 10-point scale
to rate fatigue levels can be derived from studies of other
instruments. The Brief Fatigue Inventory (BFI) is a validated
nine-item instrument for assessing fatigue in cancer patients
that includes three one-item, 0 to 10 severity scales.16 Scores
of seven or greater on both “usual level of fatigue during the
past 24 hours” and “worst level of fatigue during the past 24
hours” were associated with greater interference in function-
ing, increased symptom distress, and decreased QOL.16,17
Similarly, a score of seven of greater on a 0 to 10 scale for
fatigue is associated with functional impairment assessed by
the Medical Outcomes Study Short Form 36 (MOS-SF-36).18
There have been no studies validating the feasibility or
utility of implementing an OIFS into routine clinical care.
The goal of this study was to assess the feasibility and
validity of the OIFS in a busy outpatient oncology clinic.
Because of the high prevalence of fatigue among patients
with lung cancer, we choose a thoracic oncology clinic as our
population to investigate the practicability of the rapid one-
item screen. To investigate the scale’s validity, we also
performed comparisons to published validated instruments
for convergent and divergent validity and its ability to dis-
criminate differences in functional abilities.
PATIENTS AND METHODS
Study Population
Feasibility Study
From April 2004 until July 2004, all ambulatory pa-
tients seen in the thoracic oncology clinic at a Massachusetts
General Hospital were asked about their level of fatigue,
regardless of type of malignancy, stage of disease, or duration
of illness. Data on fatigue screening were collected over a
3-month period, beginning on the first day of the screening
program. The study was conducted with approval and mon-
itoring of the internal review board. Patients were not re-
quired to provide informed consent for participation.
Cross-Validation Study:
We obtained additional internal review board approval
for the cross-validation study on a second cohort of patients.
An additional sample of 100 patients presenting to the tho-
racic oncology clinic between October 2004 and December
2004 were recruited to participate in this study. Based on
prevalence estimates of fatigue in thoracic oncology patients,
a sample size of 100 patients was expected to yield sufficient
cases of fatigue to examine sensitivity and specificity and
cutoff scores for the OIFS. All patients presenting to the
clinic, regardless of type of malignancy, stage of disease, or
duration of illness were eligible to participate. Participants in
this study were required to read English. The medical assis-
tants informed patients that completion of the questionnaires
served as implied consent.
Procedure
Feasibility Study
A physician and nurse manager trained the medical
assistants who escort patients from the waiting room to the
examination room and assess vital signs. The training con-
sisted of a 1-hour program reviewing CRF and the NCCN
guidelines. The medical assistant placed posters with infor-
mation about CRF, including a visual analogue fatigue scale,
in each examination room.
The medical assistants were instructed to ask, “How
would you rate your fatigue on a scale of 0 to10 with 0 being
‘no fatigue’ and 10 being the ‘worst possible fatigue’?” The
medical assistants recorded the OIFS with the vital signs in
the medical record for oncologist to review before entering
the patient room.
Cross-Validation Study
The medical assistants recruited patients to complete a
packet of self-report questionnaires while waiting for their
clinic appointment. During the study period, the medical
assistants gave all patients presenting for appointments the
questionnaire packet, which included a cover letter from the
director of thoracic oncology clinic explaining that the pur-
pose of the questionnaires was to better understand CRF. The
medical assistant continued recruitment until 100 question-
naire packets were completed.
Assessments
Cross-Validation Study
The participants in the cross-validation study were
asked to complete the FACIT-F, the FSI, and the Hospital
Anxiety and Depression Scale (HADS). The medical assis-
tants also administered the OIFS in an identical fashion as the
feasibility study.
The FACIT Measurement System is a group of ques-
tions that measure health-related QOL among cancer patients.
The FACIT-F subscale is a 13-item questionnaire that as-
sesses fatigue and its impact on function. The response
format consists of a five-point Likert scale to assess fatigue
during the preceding week. FACIT-F scores range from 0 to
52, with higher scores representing lower levels of fatigue.
Scores less than 30 are considered indicative of clinically
significant fatigue.19
The FSI is a 14-item self-assessment tool to measure
the intensity and duration of fatigue and its affect on QOL.20
The questionnaire includes multiple response formats includ-
ing four questions with an 11-point scale ranging from 0 to 10
(anchored by “not fatigued at all” to “as fatigued as I could
be.” There are also seven questions inquiring about the
interference of fatigue on activity and function and three
questions to assess the duration and pattern of fatigue. A
higher score on the FSI is indicative of greater levels of
fatigue. The FSI does not have defined cutoff criteria for
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identifying clinically significant fatigue. The severity scale of
the FSI was used in all analyses.
The depression subscale of the HADS was used to
assess depression among study participants. The HADS is a
self-assessment 14-item questionnaire that has been well
tested in cancer patients. It consists of two seven-item sub-
scales assessing depression and anxiety in the preceding
week. The scale is considered appropriate for cancer patients
because of the lack of items regarding somatic symptoms,
which can confound the identification of psychiatric issues.21
The format consists of four responses that quantify the degree
to which a particular emotion is experienced by the patient.
The score on each subscale ranges from 0 to 21 and a score
greater than 11 is considered to be consistent with definitive
depression or anxiety.
Analyses
Convergent validity between the one-item fatigue
screen and the two validated measures of cancer-related
fatigue was analyzed by using Spearman correlations. As a
measure of divergent validity, scores on the one-item fatigue
screen were correlated with depression scores on the HADS.
To evaluate diagnostic utility of the OIFS, analyses
compared OIFS scores of patients with significant fatigue
versus those without significant fatigue as measured on the
FACIT-F. The FACIT-F was used as the criterion measure
because it has a validated cutoff score for designating signif-
icant fatigue.19 In a receiver operating characteristic analysis,
the calculation of the area under the curve was used to
quantify the diagnostic utility of the OIFS across the full
range of scores. Area under the curve values 0.80 are
considered good, and values 0.90 are considered excel-
lent.22 Based on the cutoff scores recommended by the
NCCN, the validity of several candidate OIFS cutoff scores
were evaluated by calculating the sensitivity and specificity
of these scores compared with the FACIT-F.
RESULTS
Feasibility
In 2004, 640 new patients were seen in the thoracic
oncology clinic. The breakdown of these new patients by
disease was approximately 58% non-small cell lung cancer,
6% small cell lung cancer, 10% esophageal cancer, 2%
mesothelioma, and 15% other (thyroid cancer, thymic malig-
nancies, adenoid cystic carcinoma, other solid tumors, or
pathology unknown). The age of these patients ranged from
25 to 91 years old, with a median of 65 years old. Women and
men compromised 47% and 53% of the population, respec-
tively.
During the 3-month study period, 600 patients partici-
pated in 1418 visits to the thoracic oncology clinic. The
number of visits per patient ranged from one to 13, with a
median of two. The medical record contained a documented
fatigue score for 96.6% of the visits. The data from the first
visit of the 600 different patients show that the medical
assistants screened 574 of the patients (95.6%) for fatigue.
The numbers and percentage of patients reporting each level
of fatigue on their initial screen is shown in Table 1. The
mean OIFS score for all patient visits was 3.4, with a standard
deviation of 3.2.
Cross-Validation
Population Description
The mean FACIT-F score for the population was 36.45
(12.11), and 30.1% of patients had FACIT-F scores of 29 or
less, meeting criteria for fatigue. Twenty-seven patients
(27%) were currently working, and the mean number of hours
was 32.9 (2.58). A few patients reported functional impair-
ments: inability to walk two blocks (15.3%), climb stairs
(18.9%), do housework (13.8%), and complete their activities
of daily living (8.2%). Four patients (4%) reported that their
fatigue interfered with their ability to make medical appoint-
ments.
Test-Retest Reliability
As a measure of test-retest reliability, we compared
scores on the OIFS obtained by the medical assistants as part
of the vital signs with the same question in written form as
one of the items of the FSI in the questionnaire packet. In
these two forms, the one-item scale had a test-retest reliability
of r  0.88.
Fatigue Scores
The screening scores from the 100 participants on the
cross-validation study were similar to the scores obtained in
the pilot screening study and suggest a representative sample.
The mean fatigue score was 3.3  2.8. The distribution of
categorical scores was also similar, with 30.9% reporting no
fatigue, 25.5% reporting mild fatigue, 26.6% reporting mod-
erate fatigue, and 17.0% reporting severe fatigue.
Correlations with Other Instruments
The OIFS was correlated with the severity scale of the
FSI at 0.87 (P  0.001) and the FACIT-F at 0.75 (P 
0.001), as shown in Table 2. This correlation is in the range
of the two validate instruments correlating with each other,
0.87 (P  0.001). Less robust correlations were found with
the depression scale of the HADS and the OIFS (0.56; P 
TABLE 1. Distribution of fatigue scores in the feasibility
sample analyzing the first observation per patient
Fatigue score Fatigue category Patients reporting score
0 None 207 (36.1)
1 Mild 19 (3.3)
2 32 (5.6)
3 37 (6.4)
4 Moderate 41 (7.1)
5 74 (12.9)
6 41 (7.1)
7 45 (7.8)
8 Severe 54 (9.4)
9 10 (1.7)
10 14 (2.4)
Values are n (%).
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0.001); the severity scale of the FSI (0.62; P  0.001); and
the FACIT-F (0.70; P  0.001).
Classification Agreement with the FACIT-F
The area under the receiver operating characteristic
curve (Figure 1) was 0.87, indicating the OIFS discriminates
effectively between those with and without significant fa-
tigue. The sensitivity and specificity of several candidate
cutoff scores indicated that OIFS scores between 3 and 5 had
adequate sensitivity (0.85) and specificity (0.61) for use
in this population (Table 3).
DISCUSSION
Over the last few years, there has been a marked
improvement in pain management based on the development
of pain as the “fifth vital sign.”23 It is routine practice for all
cancer patients to be screened for pain at each outpatient
encounter and during each inpatient hospitalization. The
implementation of this practice has broken down many of the
barriers to communication about pain between patients and
clinicians.24
Like many cancer-related symptoms, fatigue often goes
unrecognized and untreated in cancer patients. The first step
toward improving the recognition of CRF is to routinely
inquire about it in clinical practice. Although the FSI and
FACIT-F are well-validated tools for measuring fatigue in a
research setting, they are not practical as a screening modal-
ity. Treating physicians cannot immediately use the informa-
tion elicited from the FSI and the FACIT-F because the data
must be analyzed and cannot immediately be given to the
physician.
Although the NCCN guidelines advocate routine
screening with a one-item scale, there are limited data to
support the feasibility of this recommendation. Based on a
routine screening rate of more than 96%, our pilot screening
study establishes the feasibility of screening for fatigue in a
busy ambulatory oncology clinic. The results also confirm the
magnitude of the burden of CRF. Roughly half of the patients
in this study reported fatigue levels of 4 or higher, consistent
with other reports of fatigue among patients with lung can-
cer.9 The NCCN recommends that patients with a fatigue
score of 4 or greater undergo further evaluation to determine
the etiology and potential therapies for CRF. This study
uncovered a widespread, unrecognized burden among our
thoracic oncology patients.
Our data provides cross-validation for the one-item
scale for use in clinical practice. The OIFS was highly
correlated with the two validated measures of fatigue, the
FACIT-F and the severity scale of the FSI. It should be noted
that the correlation of the OIFS and the FSI severity scale is
partially because of the OIFS being included as one of the
four items of the scale. The one-item scale was less strongly
correlated with the HADS depression scale, suggesting that
depression is a related but distinct construct. This correlation
was weaker than the correlations of the FSI and FACIT-F
with depression and is similar to the mean for correlations of
fatigue and depression instruments.25
The OIFS was also effective in identifying patients who
met FACIT-F criteria for fatigue. Examining the sensitivities
and specificities of the different possible cutoff points; the
optimal cutoff score is between 3 and 5. The lower the
number chosen as a cutoff, the less likely that a possible case
of fatigue will be missed but the greater the burden in further
evaluating fatigue among the false positives. These data
support the NCCN recommended cutoff score of 4.
Although this study provides preliminary evidence re-
garding the feasibility and validity of a rapid screen for
fatigue in a specific population of ambulatory oncology
patients, further studies are needed to support these findings.
One of the limitations of this study is that we did not collect
demographic information from the study participants. This
was an observational study, and we have limited information
on the patients who were screened, other than they were
being evaluated for a thoracic malignancy. We are not able to
describe the correlation of medical variables with fatigue or
to control for confounders of fatigue such as stage of disease
TABLE 2. Correlations of one-item fatigue scale with other
measures for fatigue and depression
One-item fatigue scale FACIT-F FSI
FACIT-F 0.75
FSI 0.87 0.87
HADS 0.56 -0.70 0.62
FIGURE 1.
TABLE 3. Sensitivity and specificity values of the OIFS
compared with the FACIT-F at selected cutoff scores
One-item scale score Sensitivity Specificity
2 96.30% 46.67%
3 96.30% 61.67%
4 88.89% 76.67%
5 85.19% 80.00%
6 55.56% 88.33%
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and chemotherapy. Although these relationships are impor-
tant, this analysis was beyond the scope of this preliminary
psychometric study and has been previously described in lung
cancer patients.9 Another limitation is that this study was
performed at a single academic institution and may not be
generalizable to a community setting. However, the OIFS
was quite easy to administer by medical assistants with
limited patient experience. We therefore feel that most clin-
ical settings would be able to administer the screening tool.
Although we did assess the reliability of the OIFS, we
administered the scale in a written and oral form, rather than
repeating the oral scale. However, because the reliability was
quite robust at r  0.88, we do not believe that this method
was particularly problematic.
There is a growing body of literature for interventions
to treat and prevent CRF. There are data to support the use of
erythopoietic agents, exercise, and attention to emotional
distress to improve CRF.26–40 Screening for CRF will iden-
tify patients who are most likely to benefit from targeted
interventions for fatigue. In addition, a screening program
will identify patients who may be eligible for clinical trials to
assess therapies for fatigue.
Based on these data, the Massachusetts General Hos-
pital Cancer Center has now adopted a policy for fatigue
screening at each outpatient encounter. This information is
included in the vital signs, which are provided to the clinician
along with the pain score. We have also increased our
educational programs for patients and staff on CRF and have
developed a CRF clinic to assist with fatigue management.
Although identifying fatigue as the “sixth vital sign” may
increase the detection and recognition of this common and
distressing symptom among our patients, further studies on
the clinical utility of screening and the impact of screening on
the behavior of oncology providers and fatigue outcomes are
needed.
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